Hi Dotikers!

Yesterday, we watched Meta carefully shut the door on open source with Muse Spark, finally owning up to the fact that technological altruism has its limits when the bill runs to nine figures. Today, Anthropic plays the opposite tune: it opens Cowork to all paid subscribers, on macOS and Windows, and adds a layer of organizational controls that frankly reek of enterprise ambition.

Cowork, for those who missed the episode, is an AI assistant that runs directly on your computer. It accesses your files, launches tasks in the background, and connects to your everyday tools. This new version brings role-based access controls, per-team budgets, usage dashboards, compatibility with enterprise monitoring tools, and a Zoom integration that surfaces meeting summaries and action items directly into the work environment. Anthropic cites use cases at Zapier, Jamf, and Airtree where entire workflows were automated in a matter of days, with no engineers involved.

The strategic signal is clear: Anthropic no longer wants Cowork to remain a personal productivity tool. It wants to turn it into shared infrastructure at the organizational level, which is exactly how the Airtree team put it. The platform logic is there, and it's consistent with what we've been seeing for months across every player in the space.

What needs to be said plainly is that this rollout raises unresolved security questions. Cybersecurity researchers at PromptArmor demonstrated in January 2026 that Cowork could be manipulated to exfiltrate files simply by slipping a hidden instruction into a Word document. The identified vulnerabilities have been patched, but the underlying problem remains: as soon as an AI agent opens a file, that file can potentially trick it. Anthropic itself acknowledges this: without protections enabled, the successful attack rate reaches 17.8% on the first attempt. In other words, deploying Cowork at organizational scale also means deploying that attack surface at organizational scale.

Still, the momentum is accelerating. Microsoft is integrating the same Cowork engine into Copilot. Zoom connects natively. And while we're admiring the clean interface, the AI is quietly sorting your files and reading your emails. Worth keeping an eye on.

Alex.

Big Pharma spent decades and billions trying to solve osteoarthritis, a $500B market they’ve never cracked.

Thankfully, Cytonics figured out why they keep failing: joints are attacked by multiple culprits at once, and Big Pharma only ever went after one at a time.

So Cytonics discovered a way to get them all, creating the first therapy with the potential to actually address the root cause of osteoarthritis at the molecular level. It’s already proven across 10,000+ patients. Now, they’re pushing toward FDA approval on a 200% more potent version that can be manufactured at scale.

The first human safety trial is already complete with zero adverse events. If approved, the more than 500M osteoarthritis patients worldwide could have their long-needed solution.

Big Pharma created this opening. Now Cytonics is prepared to seize it.

And until March 26, you can claim exclusive investor bonuses and maximize your early-stage Cytonics stake.

Invest in Cytonics Now